Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tenaya Therapeutics Inc TNYA

Healthcare Biotechnology
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s... see more

Recent & Breaking News (NDAQ:TNYA)

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 18, 2024

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

GlobeNewswire March 18, 2024

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire February 27, 2024

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

GlobeNewswire February 26, 2024

Tenaya Therapeutics Announces Pricing of Underwritten Offering

GlobeNewswire February 8, 2024

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 21, 2023

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 8, 2023

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

GlobeNewswire October 26, 2023

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

GlobeNewswire October 9, 2023

Tenaya Therapeutics Doses First Patient in the MyPeak-1(TM) Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire October 5, 2023

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

GlobeNewswire October 2, 2023

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

GlobeNewswire September 21, 2023

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

GlobeNewswire August 31, 2023

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 9, 2023

Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference

GlobeNewswire August 2, 2023

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 10, 2023

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

GlobeNewswire May 3, 2023

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

GlobeNewswire May 2, 2023

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

GlobeNewswire April 21, 2023